Industry
If you would like to subscribe to Western Europe Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Western Europe Pharma & Healthcare Insight please click on the trial link below.
Boehringer Ingelheim's Pradaxa Gets European Approval
March 2008 | Product LaunchSorry, you must be a subscriber to view this article in full. If you are a subscriber please login.
If you would like to subscribe to Western Europe Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Western Europe Pharma & Healthcare Insight please click on the trial link below.
Germany's Boehringer Ingelheim has been granted marketing authorisation for its novel anticoagulant, Pradaxa (dabigatran etexilate), by the European Commission (EC). Pradaxa is a novel, oral anticoagulant and has been approved for the prevention of venous thromboembolic events in adults who have undergone elective total hip or total knee replacement surgery. It is expected that Boehringer Ingelheim will look to launch the drug in both the UK and Germany over the coming